Non-invasive monitoring of liver fibrosis
- 23 October 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in British Medical Bulletin
- Vol. 112 (1) , 97-106
Abstract
Introduction Assessing the formation and regression of fibrosis in chronic liver disease (CLD) is important. Current methods of assessment employed in clinical practice are inadequate. We present a review of the utility of non-invasive biomarkers of liver fibrosis. Sources of data Published material on MEDLINE. Areas of agreement Liver biopsy is an imperfect ‘gold standard’. Biomarkers are excellent at detecting significant fibrosis across different aetiologies of CLD. There is growing evidence that they also predict clinical outcomes. Areas of controversy Non-invasive biomarkers can be used in clinical practice to screen for significant fibrosis, but the utility of liver biopsy is retained in answering specific questions. Biomarkers cannot be used robustly in clinical trials as doubts remain over their ability to detect small changes in fibrosis, inflammation and what influences them. Areas timely for developing research Community screening and algorithms are being developed with biomarkers to more effectively direct resources. Novel imaging techniques have huge potential advantages, particularly in secondary care for risk stratification.Keywords
This publication has 46 references indexed in Scilit:
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohortJournal of Hepatology, 2012
- The harmful health effects of recreational ecstasy: a systematic review of observational evidenceHealth Technology Assessment, 2009
- Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: A general population-based studyJournal of Hepatology, 2008
- Serum markers detect the presence of liver fibrosis: A cohort studyGastroenterology, 2004
- Sampling Variability of Liver Fibrosis in Chronic Hepatitis CHepatology, 2003
- Findings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serologyJournal of Hepatology, 2001
- Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective studyThe Lancet, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- Practices of Liver Biopsy in France: Results of a Prospective Nationwide SurveyHepatology, 2000
- Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis CHepatology, 1994